Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | TTR | P02766 | 2/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287454 | 0.94 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP3A4MAPTALOX15 | |
| SCHEMBL1287515 | 0.91 | SLC22A12 (0.86) | SLC22A12CYP2C9MAPTSMN1; SMN2EYA3 | |
| SCHEMBL1287600 | 0.89 | SLC22A12 (0.88) | SLC22A12CYP2C9MAPTSMN1; SMN2EYA3 | |
| SCHEMBL1287462 | 0.86 | CYP2C9 (0.83) | SLC22A12CYP2C9CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL14495950 | 0.86 | SLC22A12 (0.70) | SLC22A12CYP2C9MAPTCYP2C19 | |
| SCHEMBL1287526 | 0.85 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP3A4MAPTEYA3 | |
| SCHEMBL1287500 | 0.83 | SLC22A12 (0.86) | SLC22A12CYP2C9MAPTSMN1; SMN2EYA3 | |
| SCHEMBL1287502 | 0.83 | SLC22A12 (1.00) | SLC22A12CYP2C9MAPTSMN1; SMN2EYA3 | |
| SCHEMBL5241747 | 0.83 | SLC22A12 (0.66) | SLC22A12CYP2C9CASP1CASP7CYP2C19 | |
| SCHEMBL1287903 | 0.82 | SLC22A12 (0.72) | SLC22A12CYP2C9MAPTSMN1; SMN2EYA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
| US-7521570-B2 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | TORLI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | HUMAN CELL SYSTEMS, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1767531-A1 | MEDICINAL COMPOSITIONS CONTAINING 6-HYDROXYBENZBROMARONE OR SALTS THEREOF | Torii Pharmaceutical Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885CYP2C9 203/4885CYP3A4 283/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885CYP2C9 203/4885CYP3A4 283/4885 |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | XDH, UGT1A6, SLC10A1 | SLC22A12 98/4885CYP2C9 295/4885CYP3A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.